Razpipadon
Razpipadon is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy. It is taken orally.
Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors.
The drug was originated by Pfizer and is under development by Cerevel Therapeutics. As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.